OR4K15: A Potential Drug Target and Biomarker for Ovarian Cancer
OR4K15: A Potential Drug Target and Biomarker for Ovarian Cancer
Ovarian cancer is the most common gynecological malignancy in the developed world, with over 21,000 new cases and 12,000 deaths per year in the United States alone. Despite advances in surgical and radiation therapy, the survival rate for ovarian cancer has remained relatively stagnant. Therefore, there is a great need for new treatments and biomarkers to improve outcomes.
One potential drug target for ovarian cancer is the OR4K15 protein, which is a subunit of the olfactory receptor OR14-20. OR14-20 is a G protein-coupled receptor (GPCR) that plays a role in sensory perception, specifically olfaction. OR14-20 has been shown to be overexpressed in various types of ovarian cancer, including epithelial, endometrial, and stromal cancers.
In addition, OR14-20 has been shown to promote the growth and survival of ovarian cancer cells in cell culture and animal models. It has also been shown to be associated with poor prognosis in ovarian cancer patients. Therefore, targeting OR14-20 may be a promising strategy for the development of new treatments for ovarian cancer.
One way to target OR14-20 is through inhibition of its activity with small molecules or antibodies. One class of small molecules that have been shown to inhibit OR14-20 activity is the inhibitors of the GPCR signaling pathway, such as Bayesian forskins-Maliowsky ( BIM) inhibitors. BIM inhibitors work by binding to the GPCR receptor and inhibiting its activity.
Another approach to targeting OR14-20 is through the use of antibodies that specifically recognize and target OR14-20. One example of an antibody that has been shown to block OR14-20 activity is an anti-OR14-20 monoclonal antibody (mAb), which is derived from a single cell and has been shown to be able to specifically recognize and inhibit OR14-20 signaling.
In addition to its potential as a drug target, OR14-20 also has the potential as a biomarker for ovarian cancer. Ovarian cancer is often associated with the expression of OR14-20, and therefore, the expression of OR14-20 may be a useful biomarker for the diagnosis and prognosis of ovarian cancer.
One way to use OR14-20 as a biomarker is through the use of RT-PCR (ribonucleic acid polymerase) assays. These assays involve the use of RNA extracted from ovarian cancer samples to amplify specific genes, including OR14-20. The amplified OR14 -20 genes can then be used to generate a protein that can be used as a marker for the diagnosis or prognosis of ovarian cancer.
Another approach to using OR14-20 as a biomarker is through the use of protein arrays. These arrays involve the use of proteins extracted from ovarian cancer samples to detect and quantify specific proteins, including OR14-20. The OR14-20 protein can then be used as a marker for the diagnosis or prognosis of ovarian cancer.
In conclusion, OR4K15 is a potential drug target and biomarker for ovarian cancer. The expression of OR14-20 is often associated with the development and progression of ovarian cancer, and targeting OR14-20 with small molecules or antibodies may be a promising strategy for
Protein Name: Olfactory Receptor Family 4 Subfamily K Member 15
Functions: Odorant receptor
The "OR4K15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR4K15 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1 | OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P
